Abstract 47P
Background
Long course radiotherapy plus neoadjuvant chemotherapy followed by resection (total mesorectal excision, TME) has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Long course (neoadjuvant chemoradiotherapy, NCRT) plus tislelizumab (a PD-1 inhibitor) followed by TME for LARC might bring better downstaging effect and reduce the risk of distant relapse.
Methods
This trial was designed to evaluate the safety and efficacy of LARC patients treated with long course NCRT plus tislelizumab followed by TME. Stage II/III LARC patients with the tumor distal location ≤ 10 cm from anal verge at six centers in China were enrolled. The patients received long course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day8), followed by TME 6-8 weeks after the end of radiotherapy. The primary endpoint will be the pathological complete response (pCR) rate.
Results
From 1st June 2021 to 10nd July 2022, 43 patients were enrolled. The median age was 63 (from 32 to 77) years while the median tumor distal location was 5.1 (from 0.1 to 9.9) cm. 30 (29 non-MSI-H/pMMR and 1 MSI-H/dMMR LARC) patients with LARC had undergone TME surgery, with R0 resection rate of 100% and sphincter saving resection rate of 90.0% (27/30). The pCR rate was 43.3 % (13/30) and objective response rate reached 100 % (30/30). Of patients without pCR, 12 (40.0 %) patients reached tumor regression grade 1 according to AJCC standard. 8 (26.7 %) immune-related adverse events including 1 patient with grade 3 diarrhea. Postoperative complications occurred in 3 (10.0 %) of 30 patients, including 1 rectovaginal fistula, 1 anastomotic leakage, and 1 intestinal obstruction, while no treatment-related death occurred.
Conclusions
Tislelizumab added to long course NCRT followed by TME exhibited favorable pCR rate with manageable toxicities and postoperative complication, including non-MSI-H/pMMR LARC. The preliminary results are promising, which provide a potential strategy for neoadjuvant therapy against LARC.
Clinical trial identification
Clinical trial information: NCT04911517.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
China Association of Gerontology and Geriatrics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02